Since the development of breast conserving therapy (BCT) that incorporated standard
fractionation whole breast irradiation (WBI) delivered daily over 5–7 weeks, there
has been a concerted effort to shorten the duration of adjuvant radiation therapy
as a way to improve convenience and compliance, reduce costs, and potentially reduce
toxicities. Over the past decade, an unprecedent shift in breast radiation techniques
and regimens has led to the emergence of shorter courses of WBI (5–15 fractions) as
well as partial breast approaches which also reduce treatment duration to 1–3 weeks.
However, the ultimate short course radiation therapy approach would be a single fraction
of treatment; intraoperative radiation therapy (IORT) offers this potential. However,
at this time, the data available supports that IORT is not an appropriate option for
patients with early stage breast cancer.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalene trial.Lancet Oncol. 2021; 22: 597-608
- Accelerated partial breast irradiation using external beam or intraoperative eletcron radiotherapy: 5 year oncological outcomes of a prospective cohort study.Int J Radiat Oncol Biol Phys. 2022; 113 (:570–81)
- Radiotherapy for breast cancer, the TARGIT-A trial.Lancet. 2014; 383: 1716
- Effect of delayed targeted intraoperative radiotherapy vs. whole-breast radiotherapy on local recurrence and survival: long-term results from the TARGIT-A randomized clinical trial in early breast cancer.JAMA Oncol. 2020; 6e200249
- Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.BMJ. 2020; 370: m2836
- An estiate of local failure in the TARGIT-A trial of pre-pathology intraoperative radiation therapy for early breast cancer.Int J Radiat Oncol Biol Phys. 2022; (:S0360–3016)
- No apparent effect of 50kv intra-operative radiation therapy on loco-regional control after lumpectomy for breast cancer.BMJ. 2020;
- TARGIT-R (retrospective): 5-year follow-up evaluation of intraoperative radiation therapy (IORT) for breast cancer performed in North America.Ann Surg Oncol. 2021; 28 (2512-21)
- Recurrence and survival rates for 1400 early breast tumors treated with intraoperative radiation therapy (IORT).Ann Surg Oncol. 2022; 29: 3726-3736
Article info
Publication history
Published online: October 11, 2022
Accepted:
August 17,
2022
Received:
May 6,
2022
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- The case for risk-stratified IORT for early breast cancerBrachytherapyVol. 21Issue 6
- PreviewDespite the significant advancement in local and systemic therapies, breast cancer remains the second leading cause of women cancer deaths (1). While adjuvant radiation therapy remains an integral part of breast cancer management (2), de-escalation strategies are increasingly being investigated. Radiation therapy de-escalation approaches entails fewer treatment days (hypofractionation), smaller target volume (partial breast irradiation -PBI-), or both (accelerated partial breast irradiation -APBI-).
- Full-Text
- Preview
